From: Diabetes, insulin use and Helicobacter pylori eradication: a retrospective cohort study
Variable | Diabetes mellitus | ||||
---|---|---|---|---|---|
No | Yes | P value | |||
n or mean | % or SD | n or mean | % or SD | ||
n (%) | 511519 | 85.05 | 89922 | 14.95 | |
Age (years) | 43.98 | 14.00 | 58.01 | 14.95 | <0.0001 |
Sex (men, %) | 253626 | 49.58 | 39950 | 44.43 | <0.0001 |
Hypertension (%) | 79292 | 15.50 | 50549 | 56.21 | <0.0001 |
Chronic obstructive pulmonary disease (%) | 105693 | 20.66 | 36273 | 40.34 | <0.0001 |
Stroke (%) | 24744 | 4.84 | 18484 | 20.56 | <0.0001 |
Nephropathy (%) | 24780 | 4.84 | 15971 | 17.76 | <0.0001 |
Ischemic heart disease (%) | 40465 | 7.91 | 28523 | 31.72 | <0.0001 |
Peripheral arterial disease (%) | 15732 | 3.08 | 12683 | 14.10 | <0.0001 |
Eye disease (%) | 1170 | 0.23 | 8763 | 9.75 | <0.0001 |
Obesity (%) | 4180 | 0.82 | 2410 | 2.68 | <0.0001 |
Dyslipidemia (%) | 51126 | 9.99 | 44973 | 50.01 | <0.0001 |
Statin (%) | 19608 | 3.83 | 24481 | 27.22 | <0.0001 |
Fibrate (%) | 16084 | 3.14 | 19053 | 21.19 | <0.0001 |
Angiotensin-converting enzyme inhibitor/ Angiotensin receptor blocker (%) | 6904 | 1.35 | 6638 | 7.38 | <0.0001 |
Calcium channel blocker (%) | 34889 | 6.82 | 18908 | 21.03 | <0.0001 |
Occupation (%) | |||||
I | 282985 | 55.32 | 35103 | 39.04 | <0.0001 |
II | 82588 | 16.15 | 17037 | 18.95 | |
III | 61580 | 12.04 | 19708 | 21.92 | |
IV | 84366 | 16.49 | 18074 | 20.10 | |
Living region (%) | |||||
Taipei | 193494 | 37.83 | 31534 | 35.07 | <0.0001 |
Northern | 74045 | 14.48 | 11182 | 12.44 | |
Central | 91087 | 17.81 | 15664 | 17.42 | |
Southern | 66785 | 13.06 | 14807 | 16.47 | |
Kao-Ping/Eastern | 86108 | 16.83 | 16735 | 18.61 | |
Panendoscopic examination in 2005 | 8211 | 1.61 | 2834 | 3.15 | <0.0001 |
Panendoscopic examination in 1997-2005 | 37759 | 7.38 | 11762 | 13.08 | <0.0001 |
Diabetic patients only | |||||
Sulfonylurea (%) | - | - | 37211 | 41.38 | |
Metformin (%) | - | - | 33106 | 36.82 | |
Insulin (%) | - | - | 6010 | 6.68 | |
Acarbose (%) | - | - | 6968 | 7.75 | |
Pioglitazone (%) | - | - | 2329 | 2.59 | |
Rosiglitazone (%) | - | - | 6538 | 7.27 |